Arthritis patients requires long-term therapy, the recent trend is to use of traditional medications in combination with allopathic drug. The objective of treatment was to suppress all inflammation and prevent joint damage. The purpose of this study was to design and development of transdermal drug delivery system (TDDS) for arthritis by using boswellic acid as a drug and evaluation of in-vivo effects. Transdermal patches were prepared by solvent evaporation method. The 32 box-behnken design was applied for the optimization of process variables. The factors involved polymer, plasticizer, penetration enhancer concentration and selected responses were flux and tensile strength. Patch was also evaluated for ex-vivo skin permeation study; in-vivo carrageenan induced paw edema and also compared with conventional NSAID patch. TDDS patch was optimized with statistical design, tensile strength was found to in the range 0.3860-0.9956 (kg/cm2) and flux 15.498-20.217 (μg/cm2/hr). Polymer, plasticizer and penetration enhancer concentration showed significantly effect on tensile strength and flux. Based on these result optimized patch subjected to ex vivo study and which shown flux 15.86 μg/cm2/hr, pharmacodynamic study showed significant reduction in the paw volume after 4th hour of inflammation induction comparable to that of NSAID patch. It was concluded that transdermal delivery of boswellic acid overcomes the main disadvantage of oral delivery which is gastric irritation and the anti-inflammatory effect thus produced via peripheral administration involves inhibition of leukotriene and other endogenous substances which are key players in pain and inflammation.
Loading....